US Prostate Cancer Nuclear Medicine Diagnostics Market to Witness an Outstanding Growth by 2027


Prostate cancer is affecting the prostate glands in the male. Prostate cancer is a common cancer following skin cancer in the male. Some common determinants responsible for the start of prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and also treat prostate cancer and helps radiologists to conclude the stage of cancer.

US prostate cancer nuclear medicine diagnostics market is driven by factors such as the rising prevalence of prostate cancer, and the growth of innovative radiopharmaceuticals plays a vital role in the growth of the radiopharmaceuticals market. However, strict guidelines for storage, production, & use of radiopharmaceuticals is likely to obstruct the growth of the US prostate cancer nuclear medicine diagnostics market during the forecast period.

Register for a free Trial today and gain instant*access @ Click Here


Top Dominating Key Players:
  1. Blue Earth Diagnostics Limited
  2. Progenics Pharmaceuticals, Inc.
  3. CURIUM
  4. Telix Pharmaceuticals Ltd.
  5. NCM-USA LLC
  6. ABX Advanced Biochemical Compounds GmbH
  7. Jubilant Radiopharma
  8. Lantheus Medical Imaging, Inc.
  9. Advanced Accelerator Applications (Novartis AG)
  10. Theragnostics

Prostate cancer (PCa) is the fourth common cancer across the US in terms of occurrence. The rising prevalence of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. For instance, according to GLOBOCAN, in 2018, there were around 2,129,118 cases of cancer in the US. Among these cases, about 10% were prostate cancer, i.e., 212,783 incidences in 2018. Moreover, the country reported 28,705 deaths due to cancer. The organization has estimated the cases of prostate cancer to reach above 737,463 in the next five years. After skin cancer, prostate cancer is the most common cancer in the American male.

Based on type, the US prostate cancer nuclear medicine diagnostics market is segmented into PET and SPECT. The PET segment held the largest share of the market in 2019 due to higher image quality and sophisticated reimbursement for the procedures as compared to the conventional SPECT nuclear medicine diagnostic processes. Radioisotopes used with PET prostate cancer diagnosis are Fluorine-18, Gallium-68, copper-64, zirconium-89, and Choline-11. Furthermore, the same segment is estimated to register the highest CAGR in the market during the forecast period.

Purchase for Report @ https://bit.ly/2XGxCIO

The US prostate cancer nuclear medicine diagnostics market, by PET product, is segmented into F-18, C-11, and Ga68-PSMA. The F-18 segment held the largest share of the market in 2019. However, Ga68-PSMA is estimated to register the highest CAGR in the market during the forecast period due to factors such as the rising prevalence of prostate cancer, technological improvements in diagnosis systems using Ga68-PSMA, and its higher sensitivity and accuracy.

Key Benefits:
  • This report provides a detailed study of market trends and forecast from 2019 to 2025, which assist to identify the prevailing market opportunities.
  • In-depth coverage of the global market that includes drivers, restraints, and opportunities, helps professionals to understand the market behavior in a better way.
  • Detailed study of the strategies of key leaders, partnerships, and acquisitions in the market is provided.


Source : Business Market Insights

Comments

Post a Comment

Popular posts from this blog

Immunochemistry Equipment Market to Reflect a Holistic Expansion During 2019 to 2027

Image
The growth of the market is driven by the factors such as, rising incidences of chronic and infectious diseases and increasing geriatric population. However, the market is likely to slower down its growth due to the limitations associated with immunohistochemistry. The countries in the region are creating significant opportunities for the key market players to expand their business. It is likely to be a major factor contributing to the market growth during the coming years. With rising costs of production against their practices, the healthcare companies are striving to produce sufficient revenue to entertain their investors. The markets in some growing economies are expected to be an essential part of offering more reliable and profitable growth opportunities for the major players to expand their industry and geographic scope. Register for a free Trial today and gain instant*access @ Click Here Key Players Influencing the Market: PerkinElmer, Inc. Abcam Plc Ag...
Read more

Biopharmaceutical Contract Manufacturing Market to Witness an Outstanding Growth by 2027

Image
The growth of the market is driven by factors such as the increasing outsourcing by pharmaceutical companies and increasing demand of biologics in the European region. However, increasing competition in the industry is likely to restrain the market growth to a certain extent. Manufacturing of Biopharmaceutical medicines through contract manufacturer from DNA to finished final product. Contract manufacturing is the type of outsourcing where a company enters into an agreement or legal settlement with another manufacturing firm for products, parts, or components, which the former will then use in its production process to complete its product. Register for a free Trial today and gain instant*access @ Click Here Key Players Influencing the Market: Lonza Group AG Boehringer Ingelheim International GmbH Inno Biologics Ventures Sdn Bhd Thermo Fisher Scientific AbbVie Inc. WuXi Biologics General Electric Samsung Biologics Merck KGaA Ajinomoto Co., Inc ...
Read more

Patient Registry Software Market Set for Rapid Growth and Trend by 2027

Image
The factors contributing to the growth of the Patient Registry Software market in Growing expenditure of digital healthcare, rising number of patients enrolling in patient registries and others. In the past few years, the Patient Registry has become a significant field in the North America medical sector, experiencing good development vision for the treatment of some challenging diseases. The government of the country organized various awareness programs for utilization of the patient registry. Moreover, the growing number of players operating across the region for patient registry software. The countries such as US and Canada are estimated to serve various growth opportunities due to the rising development in the healthcare IT sector. Register for a free Trial today and gain instant*access @ Click Here Key Players Influencing the Market: ARMUS Corporation CEDARON Dacima Software Inc. Doorn Corporation Evado Clinical FIGmd Inc. Global Vision Technologies, Inc...
Read more